BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37868989)

  • 21. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling Ewing Sarcoma Lung Metastasis.
    Dasgupta A; Kurenbekova L; Patel TD; Rajapakshe K; Ghosal G; Nirala B; Coarfa C; Yustein J
    Curr Protoc; 2023 Feb; 3(2):e670. PubMed ID: 36799651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular immunotherapy strategies for Ewing sarcoma.
    Rossig C
    Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma.
    Wagner F; Holzapfel BM; McGovern JA; Shafiee A; Baldwin JG; Martine LC; Lahr CA; Wunner FM; Friis T; Bas O; Boxberg M; Prodinger PM; Shokoohmand A; Moi D; Mazzieri R; Loessner D; Hutmacher DW
    Biomaterials; 2018 Jul; 171():230-246. PubMed ID: 29705656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
    Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
    Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.
    Murakami T; Kiyuna T; Kawaguchi K; Igarashi K; Singh AS; Hiroshima Y; Zhang Y; Zhao M; Miyake K; Nelson SD; Dry SM; Li Y; DeLong JC; Lwin TM; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Cell Cycle; 2017 Jun; 16(11):1046-1052. PubMed ID: 28296559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
    Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
    Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ewing Sarcoma PDX Models.
    Surdez D; Landuzzi L; Scotlandi K; Manara MC
    Methods Mol Biol; 2021; 2226():223-242. PubMed ID: 33326106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the tumor microenvironment of Ewing sarcoma.
    Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
    Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.
    Cohen IJ; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Feinmesser M; Avigad S; Ash S
    Cancer Chemother Pharmacol; 2019 May; 83(5):859-866. PubMed ID: 30770960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.
    Max D; Kühnöl CD; Burdach S; Niu L; Staege MS; Föll JL
    Anticancer Res; 2014 Nov; 34(11):6431-41. PubMed ID: 25368243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
    Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
    Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.
    Bosma SE; Rueten-Budde AJ; Lancia C; Ranft A; Dirksen U; Krol AD; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Fiocco M
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27943. PubMed ID: 31389188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.
    Kang Y; Armstrong AJ; Hsu DS
    Stem Cell Investig; 2022; 9():8. PubMed ID: 36393918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
    Gartrell J; Rodriguez-Galindo C
    Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.
    Morton JJ; Keysar SB; Perrenoud L; Chimed TS; Reisinger J; Jackson B; Le PN; Nieto C; Gomez K; Miller B; Gao D; Somerset H; Wang XJ; Jimeno A
    Mol Carcinog; 2018 Nov; 57(11):1651-1663. PubMed ID: 30129680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks.
    Cillo AR; Mukherjee E; Bailey NG; Onkar S; Daley J; Salgado C; Li X; Liu D; Ranganathan S; Burgess M; Sembrat J; Weiss K; Watters R; Bruno TC; Vignali DAA; Bailey KM
    Clin Cancer Res; 2022 Nov; 28(22):4968-4982. PubMed ID: 36074145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.